{"id":31314,"date":"2025-03-21T16:41:28","date_gmt":"2025-03-21T11:11:28","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=31314"},"modified":"2025-03-21T16:41:29","modified_gmt":"2025-03-21T11:11:29","slug":"encelto-for-mactel","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/encelto-for-mactel","title":{"rendered":"Neurotech\u2019s ENCELTO Makes History as the First and Only FDA-Approved Treatment for MacTel"},"content":{"rendered":"\n

Neurotech Pharmaceuticals<\/strong> has achieved a significant milestone with the recent FDA approval of its encapsulated cell therapy implant, revakinagene taroretcel<\/strong>, branded as ENCELTO<\/strong>. Approved on March 6, 2025, ENCELTO is the first treatment authorized by the FDA for macular telangiectasia (MacTel) type 2, a rare neurodegenerative eye disorder that leads to vision loss. This approval paves the way for Neurotech\u2019s commercial entry into the MacTel therapeutics market<\/a>.<\/p>\n\n\n\n

MacTel is a neurodegenerative retinal disease in adults that leads to progressive and irreversible vision loss, significantly affecting patients’ quality of life. Macular telangiectasia type 2, also known as idiopathic macular telangiectasia type 2, is a bilateral neurodegenerative disease in adults characterized by localized retinal degeneration. <\/p>\n\n\n\n

This condition leads to the gradual loss of retinal cells, resulting in vision impairment and secondary changes in the retinal vasculature \u2014 the network of blood vessels that supplies oxygen and nutrients to the retina. MacTel type 2 primarily affects middle-aged adults and typically impacts both eyes, though not always equally. It can also lead to loss of detailed vision.  <\/p>\n\n\n\n

ENCELTO, developed by Neurotech, addresses MacTel using the company’s proprietary encapsulated cell therapy (ECT) platform<\/strong>, which delivers therapeutic doses of ciliary neurotrophic factor directly to the retina to help slow disease progression.  <\/p>\n\n\n\n

Neurotech\u2019s ECT platform is a cell-based gene therapy system designed to deliver therapeutic proteins continuously for the long-term treatment of chronic eye diseases. The therapy involves an implant that is surgically placed in the vitreous of the affected eye. It contains 200,000 to 440,000 allogeneic retinal pigment epithelial (RPE) cells that have been genetically modified to produce recombinant human ciliary neurotrophic factor (CNTF). <\/p>\n\n\n\n

After surgical implantation, the implant\u2019s semipermeable membrane allows nutrients to enter while releasing therapeutic proteins into the eye, where they can migrate to the retina. The membrane also shields the encapsulated RPE cells from the host\u2019s immune response, supporting their long-term survival and sustained protein production. <\/p>\n\n\n\n

ENCELTO offers a significant advantage in convenience over other eye disorder treatments<\/a>, which typically require repeated injections or refillable implants. Currently, ENCELTO is the only approved treatment for MacTel type 2.<\/p>\n\n\n\n

\"ENCELTO-Development-Timeline\"<\/figure>\n\n\n\n

The FDA approved ENCELTO based on data from two late-stage trials, which showed that the treatment significantly slowed the loss of macular photoreceptors in MacTel patients over a 24-month period. In two phase III trials reported in late 2022, Neurotech revealed that ENCELTO\u2014previously identified as NT-501\u2014reduced the rate of MacTel progression by 56.4% and 29.2%<\/strong> compared to a simulated treatment over 24 months. <\/p>\n\n\n\n

\u201cThis is a remarkable achievement for patients, the retina community, and Neurotech,\u201d said Richard Small, Chief Executive Officer. \u201cI want to thank the clinical trial participants, investigators, and their teams, and the entire Neurotech team for making this possible.\u201d  <\/em><\/p>\n\n\n\n

Dr. Charles C. Wykoff, MD, PhD, of Retinal Consultants of Texas in Houston, TX, and a clinical investigator, shared his optimism: \u201cHaving witnessed the impact of MacTel on patients’ lives, I am confident that ENCELTO, as an FDA-approved treatment, will significantly slow disease progression and help patients maintain better functional vision over time.\u201d<\/em><\/p>\n\n\n\n

The application was reviewed under a priority process, with an initial decision expected in December 2024. However, the FDA extended the review period by about three months to evaluate additional data submitted by Neurotech. ENCELTO is expected to be available to US patients starting in June 2025<\/strong>.<\/p>\n\n\n\n

Thomas M. Aaberg Jr, MD, Chief Medical Officer, highlighted the significance of the approval: \u201cENCELTO\u2019s FDA approval marks a historic moment for the MacTel community. For those affected by this vision-threatening disease and everyone who supported this effort, today marks the beginning of a future where MacTel-related vision loss may finally be slowed.\u201d<\/em><\/p>\n\n\n\n

During the MacTel clinical trials<\/a>, the most common side effects reported included conjunctival hemorrhage, delayed dark adaptation, foreign body sensation, and eye pain. ENCELTO’s label also carries warnings about potentially serious complications, including severe vision loss, infectious endophthalmitis, retinal tears or detachment, vitreous hemorrhage, implant extrusion, and cataract formation following implantation.<\/p>\n\n\n\n

The approval of ENCELTO marks a significant milestone in the treatment landscape for MacTel. MacTel has historically lacked effective treatment options, leaving patients with limited avenues to manage their condition. ENCELTO’s approval offers new hope, providing a targeted therapy that addresses the underlying disease mechanism rather than just managing symptoms. This breakthrough could potentially slow disease progression, improve visual function, and enhance the quality of life for MacTel patients.<\/p>\n\n\n\n

Despite its promising entry, ENCELTO faces an increasingly competitive market as multiple biotech companies are advancing their own therapies for MacTel. Emerging treatments, including gene therapies, small molecules, and biologics, are gaining traction in clinical development. Companies exploring innovative delivery mechanisms, such as sustained-release implants or intravitreal injections with improved dosing schedules, may offer added convenience and improved outcomes. To maintain its competitive edge, ENCELTO’s developers will need to emphasize its unique clinical benefits, superior safety profile, and potential for long-term disease control.<\/p>\n\n\n\n

Strategic positioning will be key for ENCELTO\u2019s success. Building strong partnerships with retinal specialists, enhancing physician awareness through targeted education programs, and ensuring streamlined access to the therapy will be crucial. Additionally, securing favorable reimbursement strategies will play a pivotal role in expanding patient adoption, particularly in markets where treatment costs may present a barrier. By highlighting real-world evidence and long-term efficacy data, ENCELTO can strengthen its standing as a preferred option for both clinicians and patients.<\/p>\n\n\n\n

Ultimately, while competition in the MacTel treatment landscape<\/a> is poised to intensify, ENCELTO\u2019s early market entry presents an advantage. By proactively addressing patient needs, enhancing stakeholder engagement, and investing in post-approval research to reinforce its benefits, ENCELTO can establish itself as a cornerstone treatment in this underserved therapeutic area.<\/p>\n\n\n\n

\"Macular<\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"

Neurotech Pharmaceuticals has achieved a significant milestone with the recent FDA approval of its encapsulated cell therapy implant, revakinagene taroretcel, branded as ENCELTO. Approved on March 6, 2025, ENCELTO is the first treatment authorized by the FDA for macular telangiectasia (MacTel) type 2, a rare neurodegenerative eye disorder that leads to vision loss. This approval […]<\/p>\n","protected":false},"author":14,"featured_media":31316,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[22487,22489,22490,22475,22488],"industry":[17225],"therapeutic_areas":[17244,17234],"class_list":["post-31314","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-encelto","tag-mactel","tag-mactel-treatment","tag-macular-telangiectasia","tag-macular-telangiectasia-type-2","industry-pharmaceutical","therapeutic_areas-ophthalmology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"\nNeurotech\u2019s ENCELTO: A New Era for MacTel Treatment Begins<\/title>\n<meta name=\"description\" content=\"Neurotech Pharmaceuticals has achieved a significant milestone with the recent FDA approval of its encapsulated cell therapy implant ENCELTO.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/encelto-for-mactel\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neurotech\u2019s ENCELTO: A New Era for MacTel Treatment Begins\" \/>\n<meta property=\"og:description\" content=\"Neurotech Pharmaceuticals has achieved a significant milestone with the recent FDA approval of its encapsulated cell therapy implant ENCELTO.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/encelto-for-mactel\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-21T11:11:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-21T11:11:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/19131641\/encelto-for-mactel.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Neurotech\u2019s ENCELTO: A New Era for MacTel Treatment Begins","description":"Neurotech Pharmaceuticals has achieved a significant milestone with the recent FDA approval of its encapsulated cell therapy implant ENCELTO.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/encelto-for-mactel","og_locale":"en_US","og_type":"article","og_title":"Neurotech\u2019s ENCELTO: A New Era for MacTel Treatment Begins","og_description":"Neurotech Pharmaceuticals has achieved a significant milestone with the recent FDA approval of its encapsulated cell therapy implant ENCELTO.","og_url":"https:\/\/www.delveinsight.com\/blog\/encelto-for-mactel","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-03-21T11:11:28+00:00","article_modified_time":"2025-03-21T11:11:29+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/19131641\/encelto-for-mactel.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/encelto-for-mactel","url":"https:\/\/www.delveinsight.com\/blog\/encelto-for-mactel","name":"Neurotech\u2019s ENCELTO: A New Era for MacTel Treatment Begins","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/encelto-for-mactel#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/encelto-for-mactel#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/19131641\/encelto-for-mactel.png","datePublished":"2025-03-21T11:11:28+00:00","dateModified":"2025-03-21T11:11:29+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Neurotech Pharmaceuticals has achieved a significant milestone with the recent FDA approval of its encapsulated cell therapy implant ENCELTO.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/encelto-for-mactel"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/encelto-for-mactel#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/19131641\/encelto-for-mactel.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/19131641\/encelto-for-mactel.png","width":466,"height":284,"caption":"encelto-for-mactel"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/19131641\/encelto-for-mactel-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ENCELTO<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">MacTel<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">MacTel Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Macular Telangiectasia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Macular Telangiectasia Type 2<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">ENCELTO<\/span>","<span class=\"advgb-post-tax-term\">MacTel<\/span>","<span class=\"advgb-post-tax-term\">MacTel Treatment<\/span>","<span class=\"advgb-post-tax-term\">Macular Telangiectasia<\/span>","<span class=\"advgb-post-tax-term\">Macular Telangiectasia Type 2<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Mar 21, 2025","modified":"Updated on Mar 21, 2025"},"absolute_dates_time":{"created":"Posted on Mar 21, 2025 4:41 pm","modified":"Updated on Mar 21, 2025 4:41 pm"},"featured_img_caption":"encelto-for-mactel","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31314","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=31314"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31314\/revisions"}],"predecessor-version":[{"id":31322,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31314\/revisions\/31322"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/31316"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=31314"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=31314"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=31314"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=31314"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=31314"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}